Can-Fite BioPharma Presents Results Showing A Correlation between High Expression Of The Receptor Target For Its Drug CF101 And Rheumatoid Arthritis Patients' Response To The Drug

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, presents results showing a correlation between high expression of the receptor target for its drug CF101 the response of rheumatoid arthritis patients to treatment with the drug. These findings were obtained through analysis of the results of a phase IIa clinical trial in patients with rheumatoid arthritis (RA), and constitute substantial evidence for a correlation between the expression of the A3 adenosine receptor, the target for CF101, developed by Can-Fite, and response of patients to treatment with this drug. These findings will be presented at the annual scientific meeting of the American College of Rheumatology (ACR), which is considered one of the most prominent gatherings in the field of rheumatology.